Eric A. Hughes - Aug 1, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, Global R&D and Chief Medical Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes
Stock symbol: TEVA
Transactions as of: Aug 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 8/3/2022, 07:14 AM
Next filing: Mar 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award	$0	+211K		$0.00	211K	Aug 1, 2022	Ordinary Shares	211K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Restricted share units were granted on August 1, 2022, with 52,742 vesting on each of August 1, 2023, August 1, 2024 and August 1, 2025 and 52,744 vesting on August 1, 2026.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer